A Phase 3 interventional study of losartan potassium and Comparator: losartan in Hypertension, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2009-07-14.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 65 studies testing losartan in Hypertension — 5 open to participants now, 5 under way, 1 of them phase 3. Losartan · Hypertension.
Among the 65 studies testing losartan in Hypertension, this one is the 12th largest by enrollment, is one of 2 that started in 1991, is one of 17 in phase 3, and was the 18th registered.
6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.
Browse Hypertension studies →5 of the 65 studies testing losartan in Hypertension are open now, in 4 countries. Recruiting first, the newest first:
National Medical Research Center for Therapy and Preventive Medicine · Sites in Russia
Ages 50–70
Mayo Clinic · Sites in United States
Ages 18+
University of California, San Francisco · Sites in United States
Ages 40+
Huons Co., Ltd. · Sites in Korea, Republic of
Ages 19–64 · Healthy volunteers
Jing Liu · Sites in China
Ages 18–75
By country, each count listing its studies:
Losartan: first FDA approval 1995 (COZAAR). What it is approved for, and how studies give it, is on its page →
Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.
This study: 21 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
65 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 7 · Phase 3 18 · Phase 4 26
First in 1990; this study’s year is marked. 2 started in 1991.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 366 is above the median of 100 across 4,579 interventional studies indexed under Hypertension.
Median enrollment 100 across the 65 interventional studies. Of the 47 that completed or were terminated, 20 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 65 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
33 studies in Hypertension by Merck & Co., Inc: none open now, none under way, none of them phase 3. Of 33 finished, 27 (82%) have results posted.
Among the 33 studies in Hypertension by Merck & Co., Inc, this one is the 6th largest by enrollment of the 32 interventional ones that give a count, is one of 2 that started in 1991, is one of 9 in phase 3, and was the 11th registered.
Merck & Co., Inc’s Hypertension studies by the year they started, since 1990.
3 of the studies testing losartan in Hypertension that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07241338Jing LiuSacubitril/Allisartan for Hypertensive Patients With Overweight or Obesity | 2026-11 |
| NCT04715568University of California, San FranciscoSecondhand Tobacco Smoke and Cardiovascular Disease | 2026-12-31 |
| NCT07784621Huons Co., Ltd.A Phase 1 Clinical Trial to Evaluate the Safety and the Pharmacokinetic Drug-Drug Interaction Between HUC2A-752-A and HUC2A-752-B in Healthy Adults | 2027-02 |
Add all 3 to your calendar (.ics) → With an account.
Among the 65 studies testing losartan in Hypertension, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 33 in Hypertension:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
After a 4 week placebo period, patients were randomized to Placebo or Losartan 50 mg arms, after 6 weeks non-responders were up titrated to 100 mg losartan for the remaining 6 weeks. This study evaluated if losartan is more effective than placebo in lowering sitting diastolic blood pressure and is well tolerated in patients with mild to moderate hypertension.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo
Drug: Comparator: Placebo
Losartan 50 mg for 12 weeks
Drug: losartan potassium
Losartan 50 mg titrated to 100 mg after 6 weeks
Drug: Comparator: losartan
50 mg Losartan (MK0954) tablet taken once daily for 12 weeks.
Also known as: MK0954
50 mg tablet of Losartan (MK0954) taken once daily for 6 weeks, Non-responders will then have the dose up titrated to 100 mg for remaining 6 weeks.
Also known as: MK0954
Placebo to Losartan
Mean Change From Baseline in Trough Sitting Diastolic Blood Pressure (SiDBP) at Week 12
Mean change from baseline in trough (24 hours post dose) SiDBP at Week 12
Time frame: At baseline and at 12 weeks (24 hours post dose)
Categories of Hypertensive Response in Trough Diastolic Blood Pressure (SiDBP) at Week 6
Patients with trough SiDBP \<90 mm Hg were in Category I, ≥90 but decreased at least 10 mm Hg were in Category II, and ≥90 and decreased less than 10 mm Hg were in Category III.
Time frame: 24 hours post dose at Week 6
Categories of Hypertensive Response in Trough Diastolic Blood Pressure (SiDBP) at Week 12
Patients with trough SiDBP \<90 mm Hg were in Category I, ≥90 but decreased at least 10 mm Hg were in Category II, and ≥90 and decreased less than 10 mm Hg were in Category III.
Time frame: 24 hours post dose at Week 12
Mean Change From Baseline in Trough Sitting Diastolic Blood Pressure (SiDBP) at Week 6
Mean change from baseline in trough (24 hours post dose) SiDBP at Week 6
Time frame: At baseline and at 6 weeks (24 hours post dose)
Mean Change From Baseline in Peak Sitting Diastolic Blood Pressure (SiDBP) at Week 6
Mean change from baseline in peak (6 hours post dose) SiDBP at Week 6
Time frame: At baseline and at 6 weeks (24 hours post dose)
Mean Change From Baseline in Peak Sitting Diastolic Blood Pressure (SiDBP) at Week 12
Mean change from baseline in peak (6 hours post dose) SiDBP at Week 12
Time frame: At baseline and at 12 weeks (6 hours post dose)
Patients were recruited at 22 sites in the United States. Prime Therapy Period: December, 1991 to August, 1992.
| Milestone | Placebo | Losartan 50 mg | Losartan 50/100 mg |
|---|---|---|---|
| Started | 116 | 127 | 123 |
| Completed | 98 | 115 | 110 |
| Not completed | 18 | 12 | 13 |
| Withdrew: Adverse event | 3 | 0 | 7 |
| Withdrew: Lack of efficacy | 9 | 6 | 1 |
| Withdrew: Lost to follow-up | 2 | 3 | 1 |
| Withdrew: Protocol violation | 2 | 2 | 1 |
| Withdrew: Withdrawal by subject | 2 | 1 | 2 |
| Withdrew: Patient uncooperative | 0 | 0 | 1 |
Mean change from baseline in trough (24 hours post dose) SiDBP at Week 12
| mm Hg | Placebo | Losartan 50 mg | Losartan 50/100 mg |
|---|---|---|---|
| Mean Change From Baseline in Trough Sitting Diastolic Blood Pressure (SiDBP) at Week 12 | -4.3 ± 6.7 | -7.9 ± 7.6 | -8.6 ± 7.7 |
Patients with trough SiDBP \<90 mm Hg were in Category I, ≥90 but decreased at least 10 mm Hg were in Category II, and ≥90 and decreased less than 10 mm Hg were in Category III.
| Participants | Placebo | Losartan 50 mg | Losartan 50/100 mg |
|---|---|---|---|
| Category I | 14 | 37 | 37 |
| Category II | 8 | 20 | 21 |
| Category III | 92 | 68 | 60 |
Patients with trough SiDBP \<90 mm Hg were in Category I, ≥90 but decreased at least 10 mm Hg were in Category II, and ≥90 and decreased less than 10 mm Hg were in Category III.
| Participants | Placebo | Losartan 50 mg | Losartan 50/100 mg |
|---|---|---|---|
| Category I | 19 | 40 | 37 |
| Category II | 12 | 18 | 24 |
| Category III | 83 | 67 | 57 |
Mean change from baseline in trough (24 hours post dose) SiDBP at Week 6
| mm Hg | Placebo | Losartan 50 mg | Losartan 50/100 mg |
|---|---|---|---|
| Mean Change From Baseline in Trough Sitting Diastolic Blood Pressure (SiDBP) at Week 6 | -3.5 ± 5.8 | -6.9 ± 7.0 | -7.9 ± 7.1 |
Mean change from baseline in peak (6 hours post dose) SiDBP at Week 6
| mm Hg | Placebo | Losartan 50 mg | Losartan 50/100 mg |
|---|---|---|---|
| Mean Change From Baseline in Peak Sitting Diastolic Blood Pressure (SiDBP) at Week 6 | -4.1 ± 6.9 | -9.7 ± 8.7 | -8.9 ± 8.7 |
Mean change from baseline in peak (6 hours post dose) SiDBP at Week 12
| mm Hg | Placebo | Losartan 50 mg | Losartan 50/100 mg |
|---|---|---|---|
| Mean Change From Baseline in Peak Sitting Diastolic Blood Pressure (SiDBP) at Week 12 | -4.7 ± 7.9 | -9.5 ± 9.2 | -10.1 ± 8.6 |
| Age Continuous(years) | Placebo | Losartan 50 mg | Losartan 50/100 mg | Total |
|---|---|---|---|---|
| Mean | 53.8 (26 to 78) | 53.2 (28 to 75) | 55.1 (28 to 76) | 54.0 (26 to 78) |
| Sex: Female, Male(Participants) | Placebo | Losartan 50 mg | Losartan 50/100 mg | Total |
|---|---|---|---|---|
| Female | 42 | 44 | 45 | 131 |
| Male | 74 | 83 | 78 | 235 |
| Race/Ethnicity, Customized(participants) | Placebo | Losartan 50 mg | Losartan 50/100 mg | Total |
|---|---|---|---|---|
| Caucasian | 92 | 104 | 101 | 297 |
| Black | 17 | 14 | 16 | 47 |
| Hispanic | 7 | 8 | 4 | 19 |
| Indian | 0 | 1 | 0 | 1 |
| Oriental | 0 | 0 | 2 | 2 |
| Sitting Diastolic Blood Pressure (SiDBP)(mm Hg) | Placebo | Losartan 50 mg | Losartan 50/100 mg | Total |
|---|---|---|---|---|
| Mean | 101.3 (95 to 115) | 102.2 (95 to 113) | 102.2 (95 to 114) | 101.9 (95 to 114) |
No study locations are listed for this record.
The record gives a start of Dec 1991, a primary completion of Aug 1992 and a completion of Nov 1992. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2009, 16 years 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Losartan